SOPHiA GENETICS (NASDAQ:SOPH) CFO George Cardoza Sells 1,592 Shares of Company Stock

Key Points

• CFO George Cardoza sold 1,592 shares of SOPHiA GENETICS at an average price of $8.10, totaling $12,895.20. The pre-arranged Rule 10b5-1 sale was made to cover tax obligations tied to vested equity awards, leaving him with 306,726 shares.
• SOPH shares recently traded at $7.15, while the company reported a quarterly loss of $0.26 per share, missing estimates, despite revenue of $23.31 million exceeding expectations. Analysts expect a full-year loss of $0.77 per share.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $10.00 price target. Three analysts rate the stock Buy, one rates it Hold, and one rates it Sell.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CFO George Cardoza sold 1,592 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.10, for a total value of $12,895.20. Following the completion of the sale, the chief financial officer directly owned 306,726 shares of the company's stock, valued at approximately $2,484,480.60. This trade represents a 0.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Monday, September 21st, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.33, for a total value of $6,447.42.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH traded down $0.23 on Wednesday, reaching $7.15. The stock had a trading volume of 432,750 shares, compared to its average volume of 308,157. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a 12-month low of $3.75 and a 12-month high of $8.98. The business's 50-day moving average price is $7.82 and its 200 day moving average price is $6.12. The stock has a market cap of $599.81 million, a P/E ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
• Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
• Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently made changes to their positions in SOPH. Maven Securities LTD purchased a new position in SOPHiA GENETICS during the second quarter worth about $866,000. AXQ Capital LP purchased a new stake in SOPHiA GENETICS in the 2nd quarter valued at approximately $119,000. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS in the 2nd quarter valued at approximately $9,809,000. Hennion & Walsh Asset Management Inc. acquired a new position in SOPHiA GENETICS during the 2nd quarter worth approximately $567,000. Finally, Royal Bank of Canada increased its position in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after purchasing an additional 18,781 shares during the period. Institutional investors and hedge funds own 31.59% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on SOPH shares. Zacks Research raised shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. HC Wainwright increased their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. BTIG Research upped their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.